CN105801655B - Purposes of the monodisperse polymer silica gel in Rg1, Re and Rb1 purification - Google Patents
Purposes of the monodisperse polymer silica gel in Rg1, Re and Rb1 purification Download PDFInfo
- Publication number
- CN105801655B CN105801655B CN201410838243.2A CN201410838243A CN105801655B CN 105801655 B CN105801655 B CN 105801655B CN 201410838243 A CN201410838243 A CN 201410838243A CN 105801655 B CN105801655 B CN 105801655B
- Authority
- CN
- China
- Prior art keywords
- ginsenoside
- purposes
- silica gel
- ethyl alcohol
- monodisperse polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to purposes of the monodisperse polymer silica gel in Rg1, Re and Rb1 purification, this method is mainly the use for passing through monodisperse polymer silica gel in Rg1, Re and Rb1 purification, and Rg1, Re and Rb1, high separation is purified from arasaponin.
Description
Technical field
The present invention relates to field of medicine invention, and in particular to monodisperse polymer silica gel is in ginsenoside Rg1, ginsenoside Re
With the purposes in ginsenoside Rb1's purification.
Background technique
Arasaponin derives from pseudo-ginseng, and main component includes notoginsenoside R, ginsenoside Rg1, ginsenoside
Re, ginsenoside Rb1 and ginsenoside Rd.It is usually used in promoting blood circulation, promotes blood circulation active, to hyperlipidemia, hypercoagulable blood, to high blood
The pharmacological action of pressure, while having the effects that resist myocardial ischemia, antiatherosclerosis, antithrombotic, anti-cardiac-cerebral ischemia, clinic is main
It to be prepared into full ingredient based on preparation, have no single component or in which combination preparation.
There are prevention and treatment to cardiovascular and cerebrovascular disease.Patent application CN101116669, discloses ginsenoside
Rg3, ginseng saponin Rh 2 and several compositions of ginsenoside the III auxiliary that caused leucocyte reduces after preventing chemicotherapy are used
Medicine.
Patent application CN 1305479C discloses the low polarity ginsenoside such as ginsenoside Rg 5, Rk1, Rg3, Rh2, Rg5
Composition and its feature with anticancer activity.
Ginsenoside Rg1 has substantially the biosynthesis effect and the effect of the biosynthesis to DNA of protein or lipid
Same tendency；It can be reduced the contraction in guinea pig in vitro uterus caused by phatidylcholine；There are reducing heart rate and amphicheirality's blood pressure to make rat
With (falling after rising)；There are diastole animal blood vessels and antifatigue effect.
Ginsenoside Re: inhibiting nervous centralis, promotes DNA, RNA synthesis.The effect of plasma corticosterone is increased, blood is expanded
Pipe.It can be reduced the contraction in guinea pig in vitro uterus caused by acetylcholine.There are reducing heart rate and Bipolar blood pressure (after first rising rat
Drop) effect.Behavior and electroencephalogram to cat show medium inhibition.There is antifatigue effect.
Ginsenoside Rb1 is soluble easily in water, methanol, ethyl alcohol, does not dissolve in ether, benzene.Central nervous system, cardiovascular system
System, digestive system, immune system, endocrine system, urogenital system have extensive effect, so that human body power, intelligence can be improved
The mobility of power, nonspecific resistance of the enhancing body to destructive stimulus.
Arasaponin purification process is aided with the common removal of impurities means such as aluminium oxide, active carbon based on chromatographic purifying technique,
Primary product includes each saponins and sapogenin, and purity is about 85%, is had no for the wherein extraction of each component, purification process.
Current not disclosed notoginsenoside R, ginsenoside Rb1 are purified to 95% or more extraction process.
Silica gel and polymer be the filler of matrix be the essential two kinds of performances of chromatographic isolation and analysis field each other
The chromatographic media of supplement.Silica matrix mechanical strength is big, column effect is high, good resolution, be widely used to organic compound and in
Property molecule analysis and large scale preparation production in；And polymer substrate filler then have good chemical stability and without with than
Quasi- resistance to acid and alkali, therefore the service life is long, can on-line cleaning be suitble to the large scale purification separation of biomolecule.Research has shown that, due to
In the difference of material in silica gel and polymer chromatography filler, they have extremely strong mutual in terms of to target molecule separation selectivity
Benefit property, is difficult isolated substance with polymer filler Ru some, good separation can be but obtained on silica filler；On the contrary, one
It is difficult isolated substance on silica filler a bit, and can be efficiently separated with polymer filler.
Monodisperse refers to that some parameter of substance has uniform property.Such as monodisperse system typically refers to dispersed phase kind
The dispersion of single and Unusually narrow particle size distribution (i.e. the partial size overwhelming majority is equal), particle diameter distribution are in normal distribution, and monodisperse is small
Ball refers to the highly uniform bead of shape size.
For existing ginsenoside Rg1, ginsenoside Re and the not high problem of ginsenoside Rb1's purity, inventor passes through
A large amount of research, finally proposes the present invention.
Summary of the invention
The object of the present invention is to provide purposes of the monodisperse polymer silica gel in ginsenoside Rg1, Re and Rb1 purification.
Preferably: the monodisperse polymer silica gel is the monodisperse polymer silica gel of amino sealing.
Monodisperse polymer silica gel application method of the present invention are as follows: nonpolar macroporous in arasaponin purifies and separates
The monodisperse polymer silica gel of absorption resin-bonded amino sealing is for adsorbing-eluting ginsenoside Rg1, Re and Rb1
Monodisperse polymer silica gel application method of the present invention are as follows:
1) after taking arasaponin that ethyl alcohol is added to dissolve, neopelex is added, after dissolution, is loaded into nonpolar big
On macroporous adsorbent resin, with ethanol elution, gained eluent is collected, is concentrated and dried；
2) it takes dry product obtained by step 1) that ethyl alcohol is added to dissolve, is loaded into using monodisperse polymer silica gel as the chromatographic column of filler
On, gradient elution is made at a constant temperature with 80%-50% ethyl alcohol, eluent is with UV detector on-line checking ginsenoside Rg1, Re
With Rb1 content；
3) Fractional Collections eluent, using ultraviolet absorptivity as foundation, discard no ginsenoside Rg1, Re and Rb1 part and
Impurity peak area is higher than 5% part, remaining merging, gained collection liquid is concentrated and dried to get ginsenoside Rg1, Re and Rb1.
Preferably: the step 2) nonpolar macroporous adsorption resin is the nonpolar macroporous suction that ethyl styrene is skeleton
Attached resin.
Preferably: the step 2) nonpolarity macroporous adsorptive resins chromatographic column, chromatographic column diameter height compare for 1:5-20.
Preferably: step 2) the neopelex additional amount is the 0.5-3% of ethyl alcohol weight.
Preferably: the step 3) dry product adds ethyl alcohol to dissolve, concentration of alcohol 50-70%.
Preferably: the monodisperse polymer silicagel column of step 3) the amino sealing, chromatographic column diameter height compare for 1:5-50.
Preferably: ethyl alcohol constant temperature elutes in the step 2), and temperature is 10-60 DEG C.
Preferably: UV detector on-line checking in the step 2), UV absorption wavelength are 200-210nm.
Preferably: arasaponin in the step 1), refer to from Radix Notoginseng using water mention or alcohol extracting obtained by, wherein containing
Notoginsenoside R, ginsenoside Rg1, ginsenoside Re, ginsenoside Rb and ginsenoside Rd.
Raw material sources:
Arasaponin: PANAX NOTOGINSENOSIDES, molecular formula C47H80O17, from the activity of Radix Notoginseng extraction
Effective ingredient.[preparation] XUESAITONG ZHUSHEYE, XUESHUANTONG ZHUSHEYE, Radix Notoginseng total glucosides tablet, notoginseng total saponin capsule.[character] this product is
Faint yellow amorphous powder, bitter, micro-sweet.Arasaponin is to be extracted from high-quality Radix Notoginseng according to extracting and developing technology effectively
Medicinal ingredient include more than 20 kinds of saponin(e active materials, 17 kinds of microelements, albumen, vitamin abundant, polysaccharide etc..[function
Cure mainly] promoting blood circulation, it promotes blood circulation active, has the function of inhibiting platelet aggregation and increase heart and brain blood flow.
Silica gel is a kind of high activity adsorbent material, belongs to amorphous substance, main component is silica, chemical molecular formula
For mSiO2·nH2O.Itself there is no toxicity, chemical property is stablized, do not burn.Not soluble in water and any solvent removes highly basic, hydrogen
It does not react with any substance outside fluoric acid.Mainly it is used as desiccant, moisture-proof pearl, eliminating smell agent and various adsorbents, and purification
Kerosene, absorption aromatic hydrocarbons etc., produce in the essential industries product such as melamine, phthalic anhydride, maleic anhydride, butadiene rubber, acrylonitrile
In be used as catalyst and catalyst carrier.
The polarity of polar binding phase aminopropyl Aminopropyl (- Si (CH2) 3NH2) is bonded in high-purity silica gel matrix
Adsorbent, while there is two kinds of mechanisms of action of hydrogen bond and anion exchange, end group sealing.Due to the work for the propyl being connected with amino
With so that amino shows low pole, therefore can be used to separate nonpolarity from polarity sample and divide compound, but it is highly polar also
It is the key property of amino.
The work that the present invention is purified by the monodisperse polymer silica gel of nonpolar macroporous adsorption resin combination amino sealing
The composition high separation of process, the monomer component ginsenoside Rg1 that can be will be present in pseudo-ginseng, Re and Rb1 purifies
After obtain, the effect of the composition tool is alleviated with the treatment symptoms such as angina pectoris and cardiac arrhythmia, have to the treatment of cardiovascular disease
It has the certain significance.
Monodisperse polymer silica gel provided by the invention is in ginsenoside Rg1, ginsenoside Re and ginsenoside Rb1 purify
Purposes have the advantage that
1, poly- using the monodisperse of nonpolar macroporous adsorption resin combination amino sealing in arasaponin purification process
Silica gel absorption ginsenoside Rg1, ginsenoside Re and ginsenoside Rb1 are closed, the ginsenoside of 90% or more purity can be obtained
Rg1, ginsenoside Re and ginsenoside Rb1.
2, this technology purifying resulting composition safety testing shows that toxicity is extremely low.Acute toxicity median lethal dose half
Lethal dose LD50 is 858.37mg/kg, and 95% credible is limited to 774.29~961.59mg/kg.
Specific embodiment
The present invention is further illustrated below by embodiment.It should be understood that the embodiment of the present invention is for illustrating
The present invention is rather than limiting the invention.The simple modifications that essence according to the present invention carries out the present invention belong to the present invention
Claimed range.Unless otherwise indicated, the percentage of the amount of alcohol in the present invention is percentage by volume, and v/v indicates solution
Volume ratio, BV be column volume multiple, as 1BV be 1 times of column volume.
Embodiment 1: the preparation method of arasaponin
Pseudo-ginseng 1000g is taken, 60 DEG C of the 60% ethyl alcohol heating and refluxing extraction 2 times of 5 times of three seven weight, first time 3 is added
Hour, second 2 hours, combined extract, filtering, it was 1.20, after concentrate degreasing that filtrate, which is concentrated into relative density, gained leaching
Cream crosses D101 macroporous absorbent resin absorption-elution, and eluent concentration, drying after aluminium oxide, activated carbon adsorption decoloration obtains three
Seven total saposins.
Embodiment 2: the preparation method of arasaponin
It takes Radix Notoginseng to be ground into coarse powder 1000g, 80% ethyl alcohol 8000ml is added to extract 7 hours, collect extracting solution, filtering takes filter
Liquid recycles ethyl alcohol to no alcohol taste, adds water that the solution of every 1ml crude drug containing 0.5g is made, crosses macroporous resin column and alumina adsorption, uses
65% ethanol elution, eluent concentration, drying, obtains arasaponin.
Embodiment 3: the preparation method of arasaponin
Radix Notoginseng is taken, 20 mesh coarse powder are made, is extracted 2 times with ethyl alcohol, adds 10 times 70% of ethyl alcohol every time, extracts 3 hours every time,
Combined extract, filtration take filtrate recycling ethanol to no alcohol taste, cross the large pore resin absorption column absorption of 8 times of three seven weight, collect
Eluent, adsorption bleaching, recycling design, concentration, low temperature drying obtain arasaponin.
Embodiment 4:
1) take arasaponin that concentration is added to be the dodecyl benzene sulfonic acid of addition ethyl alcohol weight 1% after the dissolution of 20% ethyl alcohol
Sodium, after dissolution, be loaded into diameter height than for 1:10, using ethyl styrene as on the nonpolar macroporous adsorption resin of skeleton, 3 times of cylinders
60% ethanol elution of product is collected gained eluent, is concentrated and dried；
2) it takes dry product obtained by step 2) that 60% ethyl alcohol is added to dissolve, is loaded into and is with the monodisperse polymer silica gel of amino sealing
On the chromatographic column of filler, diameter height compares for 1:10, makees gradient elution under 20 DEG C of constant temperature with 80%-50% ethyl alcohol, eluent is purple
External detector on-line checking ginsenoside Rg1, Re and Rb1 content, UV absorption wavelength are 203nm；
3) Fractional Collections eluent, using ultraviolet absorptivity as foundation, discard no ginsenoside Rg1, Re and Rb1 part and
Impurity peak area is higher than 5% part, merges rest part (testing result is shown in Table 1), and it is dry to get ginseng to set 60 DEG C of vacuum concentrations
Saponin(e Re and ginsenoside Rd.
As a result detect: ginsenoside Rg1, ginsenoside Re and ginsenoside Rb1's composition ratio are 1:0.5:1, purity
About 92%.
Embodiment 5:
1) take arasaponin that concentration is added to be the detergent alkylate sulphur of addition ethyl alcohol weight 0.5% after the dissolution of 20% ethyl alcohol
Sour sodium, after dissolution, be loaded into diameter height than for 1:5, using ethyl styrene as on the nonpolar macroporous adsorption resin of skeleton, 3 times of columns
50% ethanol elution of volume is collected gained eluent, is concentrated and dried；
2) it takes dry product obtained by step 2) that 70% ethyl alcohol is added to dissolve, is loaded into and is with the monodisperse polymer silica gel of amino sealing
On the chromatographic column of filler, diameter height compares for 1:5, makees gradient elution under 10 DEG C of constant temperature with 80%-50% ethyl alcohol, and eluent is with ultraviolet
Detector on-line checking ginsenoside Rg1, Re and Rb1 content, UV absorption wavelength are 200nm；
3) Fractional Collections eluent, using ultraviolet absorptivity as foundation, discard no ginsenoside Rg1, Re and Rb1 part and
Impurity peak area is higher than 5% part, merges rest part, and it is dry to get ginsenoside Re and ginseng soap to set 60 DEG C of vacuum concentrations
Glycosides Rd.
As a result detect: ginsenoside Rg1, ginsenoside Re and ginsenoside Rb1's composition ratio are 1:0.5:1, purity
About 90%.
Embodiment 6:
1) take arasaponin that concentration is added to be the dodecyl benzene sulfonic acid of addition ethyl alcohol weight 3% after the dissolution of 30% ethyl alcohol
Sodium, after dissolution, be loaded into diameter height than for 1:20, using ethyl styrene as on the nonpolar macroporous adsorption resin of skeleton, 3 times of cylinders
40% ethanol elution of product is collected gained eluent, is concentrated and dried；
2) it takes dry product obtained by step 2) that 50% ethyl alcohol is added to dissolve, is loaded into and is with the monodisperse polymer silica gel of amino sealing
On the chromatographic column of filler, diameter height compares for 1:50, makees gradient elution under 60 DEG C of constant temperature with 80%-50% ethyl alcohol, eluent is purple
External detector on-line checking ginsenoside Rg1, Re and Rb1 content, UV absorption wavelength are 210nm；
3) Fractional Collections eluent, using ultraviolet absorptivity as foundation, discard no ginsenoside Rg1, Re and Rb1 part and
Impurity peak area is higher than 5% part, merges rest part, and it is dry to get ginsenoside Re and ginseng soap to set 60 DEG C of vacuum concentrations
Glycosides Rd.
As a result detect: ginsenoside Rg1, ginsenoside Re and ginsenoside Rb1's composition ratio are 1:0.5:1, purity
About 95%.
Experimental example 1: piecewise acquisition HPLC determination data, content detection data are shown in Table 1 in 4 operating process of embodiment.
Table 1: UV absorbance detection result
Table 1 is as the result is shown: using the monodisperse polymer silica gel purification point of nonpolar macroporous adsorption resin combination amino sealing
From arasaponin, ginsenoside Rg1, ginsenoside Re and ginsenoside Rb1's appearance highly concentrated period in eluent,
There is obvious deviation with the high crest segment of impurity, therefore can use technical solution of the present invention purifies and separates ginsenoside Rg1, ginsenoside
Re and ginsenoside Rb1.
Experimental example 2: the acute toxicity tests
Toxicity test is carried out to 1 sample of the embodiment of the present invention referring to 2010 editions " Chinese Pharmacopoeia " acute toxicity test methods.With
Weighted regression probability method (Bliss method) calculates, and experimental result is shown in Table 2.
3. acute toxicity result (n=10) of table
Table 2 the result shows that: median lethal dose LD50 is 858.37mg/kg, and 95% credible is limited to 774.29~961.59mg/
Kg, toxicity highly-safe using the ginsenoside Rg1 of purification & isolation of the present invention, ginsenoside Re and ginsenoside Rb1's composition
It is minimum.
Although above having used general explanation, specific embodiment and test, the present invention is made to retouch in detail
State, but on the basis of the present invention, it can be made it is some modify or improve, this is aobvious and easy to those skilled in the art
See.Therefore, these modifications or improvements without departing from theon the basis of the spirit of the present invention, belong to claimed
Range.
Claims (10)
1. purposes of the monodisperse polymer silica gel of amino sealing in Rg1, Re and Rb1 purification, which is characterized in that described single point
Dissipate polymerization silica gel application method are as follows: in arasaponin purifies and separates, nonpolar macroporous adsorption resin combination amino sealing
Monodisperse polymer silica gel is for adsorbing-eluting ginsenoside Rg1, Re and Rb1.
2. purposes as described in claim 1, which is characterized in that the monodisperse polymer silica gel application method of the amino sealing
Are as follows:
1) after taking arasaponin that ethyl alcohol is added to dissolve, neopelex is added, after dissolution, is loaded into nonpolar macroporous suction
On attached resin, with ethanol elution, gained eluent is collected, is concentrated and dried；
2) it takes dry product obtained by step 1) that ethyl alcohol is added to dissolve, is loaded into using monodisperse polymer silica gel as on the chromatographic column of filler, with
80%-50% ethyl alcohol makees gradient elution, eluent UV detector on-line checking ginsenoside Rg1, Re and Rb1 at a constant temperature
Content；
3) Fractional Collections eluent discards no ginsenoside Rg1, Re and the part Rb1 and impurity using ultraviolet absorptivity as foundation
Peak area is higher than 5% part, remaining merging, gained collection liquid is concentrated and dried to get ginsenoside Rg1, Re and Rb1.
3. purposes as claimed in claim 2, which is characterized in that the step 1) nonpolar macroporous adsorption resin is ethylo benzene
Ethylene is the nonpolar macroporous adsorption resin of skeleton.
4. purposes as claimed in claim 3, which is characterized in that the step 1) nonpolarity macroporous adsorptive resins chromatographic column, chromatographic column
Diameter height compares for 1:5-20.
5. purposes as claimed in claim 2, which is characterized in that step 1) the neopelex additional amount is ethyl alcohol
The 0.5-3% of weight.
6. purposes as claimed in claim 2, which is characterized in that the step 2) dry product adds ethyl alcohol to dissolve, and concentration of alcohol is
50-70%.
7. purposes as claimed in claim 2, which is characterized in that the monodisperse polymer silicagel column of step 2) the amino sealing,
Chromatographic column diameter height compares for 1:5-50.
8. purposes as claimed in claim 2, it is characterised in that: ethyl alcohol constant temperature elutes in the step 2), temperature 10-60
℃。
9. purposes as claimed in claim 2, which is characterized in that UV detector on-line checking in the step 2), ultraviolet suction
Receipts wavelength is 200-210nm.
10. purposes as claimed in claim 2, it is characterised in that: arasaponin in the step 1) refers to and adopts from Radix Notoginseng
Mentioned with water or alcohol extracting obtained by, wherein contain notoginsenoside R, ginsenoside Rg1, ginsenoside Re, ginsenoside Rb and ginseng soap
Glycosides Rd.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410838243.2A CN105801655B (en) | 2014-12-30 | 2014-12-30 | Purposes of the monodisperse polymer silica gel in Rg1, Re and Rb1 purification |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410838243.2A CN105801655B (en) | 2014-12-30 | 2014-12-30 | Purposes of the monodisperse polymer silica gel in Rg1, Re and Rb1 purification |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105801655A CN105801655A (en) | 2016-07-27 |
| CN105801655B true CN105801655B (en) | 2018-12-18 |
Family
ID=56979892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410838243.2A Active CN105801655B (en) | 2014-12-30 | 2014-12-30 | Purposes of the monodisperse polymer silica gel in Rg1, Re and Rb1 purification |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105801655B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5425930A (en) * | 1993-09-17 | 1995-06-20 | Alliedsignal Inc. | Process for forming large silica spheres by low temperature nucleation |
| CN101575357A (en) * | 2008-05-09 | 2009-11-11 | 澳门大学 | Method for preparing notoginsenoside R1 and ginsenoside Rg1, Re, Rb1 and Rd |
| CN102350325A (en) * | 2011-07-12 | 2012-02-15 | 北京化工大学 | Preparation method of high-purity monodisperse silica-based chromatographic packing |
| CN103655653A (en) * | 2011-09-27 | 2014-03-26 | 广西梧州制药（集团）股份有限公司 | Application of macroporous weakly acidic rosin based cationic exchange resin to adsorption of toxic ingredients in panax notoginseng saponins |
-
2014
- 2014-12-30 CN CN201410838243.2A patent/CN105801655B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5425930A (en) * | 1993-09-17 | 1995-06-20 | Alliedsignal Inc. | Process for forming large silica spheres by low temperature nucleation |
| CN101575357A (en) * | 2008-05-09 | 2009-11-11 | 澳门大学 | Method for preparing notoginsenoside R1 and ginsenoside Rg1, Re, Rb1 and Rd |
| CN102350325A (en) * | 2011-07-12 | 2012-02-15 | 北京化工大学 | Preparation method of high-purity monodisperse silica-based chromatographic packing |
| CN103655653A (en) * | 2011-09-27 | 2014-03-26 | 广西梧州制药（集团）股份有限公司 | Application of macroporous weakly acidic rosin based cationic exchange resin to adsorption of toxic ingredients in panax notoginseng saponins |
Non-Patent Citations (1)
| Title |
|---|
| 单分散二氧化硅颗粒的研究进展;董鹏;《自然科学进展》;20000331;第10卷(第3期);201-207 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105801655A (en) | 2016-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ma et al. | Preparative separation and purification of rosavin in Rhodiola rosea by macroporous adsorption resins | |
| CN106588616B (en) | A kind of preparation method of curcumin | |
| CN102633895B (en) | Extraction and preparation method by comprehensively utilizing liquorice | |
| CN103601769B (en) | A kind of preparation technology of extraction separation and purification picroside Ⅰ and Picroside II from Rhizoma Picrorhizae | |
| CN102423329B (en) | A kind of discoloration method of panax notoginsenoside extract | |
| CN107510710A (en) | A kind of method and medical usage that diabetes B target spot inhibitor is enriched with from Glycyrrhiza uralensisFisch residue | |
| Wu et al. | Green and efficient extraction of total glucosides from Paeonia lactiflora Pall.‘Zhongjiang’by subcritical water extraction combined with macroporous resin enrichment | |
| CN102134268B (en) | Method for preparing panax japonicus saponin IVa and application of panax japonicus saponin IVa in preparing a medicament for protecting liver and lowering transaminase | |
| CN105801656B (en) | The method that Rg1, Re and Rb1 are purified from arasaponin | |
| WO2012061984A1 (en) | Method for preparing albiflorin and paeoniflorin | |
| CN101386614B (en) | Method for preparing epigallocatechin-3-gallate by resin adsorption method | |
| WO2012019373A1 (en) | Method for preparing paeoniflorin and albiflorin | |
| CN104844547B (en) | A kind of high efficiency extraction of barbaloin and grading purification method | |
| CN105801655B (en) | Purposes of the monodisperse polymer silica gel in Rg1, Re and Rb1 purification | |
| CN103351373B (en) | Method for extracting Schisandrin B from Schisandra chinensis | |
| CN107011405B (en) | A kind of preparation method of Panaxatriol saponin | |
| CN103044253B (en) | Extraction separation method of rosmarinic acid in salvia castabea diels f. tomentosa stib | |
| CN105797675B (en) | Purposes of the monodisperse polymer silica gel in R1 and Rb1 purification | |
| CN105796577B (en) | The method of R1 and Rb1 is purified from arasaponin | |
| CN105801659B (en) | Purposes of the monodisperse polymer silica gel in ginsenoside Re and Rd purification | |
| CN105031178A (en) | Extracting refining method making efficient utilization of anemarrhena asphodeloides | |
| CN112851621B (en) | Total iridoid extract of caulis et folium fici Tikouae, extraction and purification method and application thereof | |
| CN105801657B (en) | The method that ginsenoside Re and Rd are purified from arasaponin | |
| CN106946833A (en) | A kind of method that high-purity sinensetin is extracted from Mao Xu Cao | |
| CN102389456A (en) | Method for extracting isodon japonica var.galaucocalyx total diterpenoids or Glaucocalyxin A |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |